FDA Hits Guardian Drug for Lack of Quality Controls, Secure Data Post author:Sam Post published:April 11, 2017 Post category:Drug Industry Daily The FDA cited Guardian Drug Company over quality and data storage issues. Source: Drug Industry Daily You Might Also Like Advisory Committee Unanimously Recommends Avastin, Herceptin Biosimilars July 13, 2017 Neurocrine’s Bid for Diurnal Could Snag Phase 3 CAH Drug August 30, 2022 Merck and Glenmark Face Class Action Over Zetia Monopoly Claims January 19, 2018
